Intravenous Minocycline: A Review in Acinetobacter Infections.

Abstract:

:Intravenous minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp. Minocycline is a synthetic tetracycline derivative that was originally introduced in the 1960s. A new intravenous formulation of minocycline was recently approved and introduced to address the increasing prevalence of multidrug-resistant (MDR) pathogens. Minocycline shows antibacterial activity against A. baumannii clinical isolates worldwide, and exhibits synergistic bactericidal activity against MDR and extensively drug-resistant (XDR) A. baumannii isolates when combined with other antibacterial agents. In retrospective studies, intravenous minocycline provided high rates of clinical success or improvement and was generally well tolerated among patients with MDR or carbapenem-resistant A. baumannii infections. While randomized clinical trial data would be useful to fully establish the place of minocycline in the management of these infections for which there are currently very few available options, clinical trials in patients with infections due to Acinetobacter spp. are difficult to perform. Nevertheless, current data indicate a potential role for intravenous minocycline in the treatment of patients MDR A. baumannii infections, particularly when combined with a second antibacterial agent (e.g. colistin).

journal_name

Drugs

journal_title

Drugs

authors

Greig SL,Scott LJ

doi

10.1007/s40265-016-0636-6

subject

Has Abstract

pub_date

2016-10-01 00:00:00

pages

1467-1476

issue

15

eissn

0012-6667

issn

1179-1950

pii

10.1007/s40265-016-0636-6

journal_volume

76

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Everolimus.

    abstract::Everolimus is an immunosuppressant that blocks growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Oral everolimus 0.75 or 1.5mg twice daily significantly reduced the incidence of the primary composite endpoint, efficacy failure 6 months after transplantation, compared with azathioprine...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200464080-00005

    authors: Chapman TM,Perry CM

    更新日期:2004-01-01 00:00:00

  • Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.

    abstract::Budesonide MMX(®) (Cortiment(®); Uceris(®)) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX(®)) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients with active, mild...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0396-8

    authors: Hoy SM

    更新日期:2015-05-01 00:00:00

  • Current treatment recommendations for topical burn therapy.

    abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040030-00004

    authors: Monafo WW,West MA

    更新日期:1990-09-01 00:00:00

  • General considerations when treating hypertension.

    abstract::Numerous intervention studies have clearly demonstrated the value of antihypertensive treatment. By lowering diastolic blood pressure 5 to 6mm Hg in middle-aged hypertensive patients, a 42% reduction in stroke morbidity and a 14% reduction in coronary heart disease morbidity can be obtained. Recently published large i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300462-00008

    authors: Hansson L

    更新日期:1993-01-01 00:00:00

  • Cholinesterase inhibitors for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available. Cholinestera...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161010-00005

    authors: Grutzendler J,Morris JC

    更新日期:2001-01-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Clinical evidence with montelukast in the management of chronic childhood asthma.

    abstract:OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059001-00005

    authors: Becker A

    更新日期:2000-01-01 00:00:00

  • Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.

    abstract::Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. However, the majority of patients with NSCLC will ultimately develop resistance to initial platinu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0628-6

    authors: Barnfield PC,Ellis PM

    更新日期:2016-09-01 00:00:00

  • Antiepileptic drug development in children: considerations for a revisited strategy.

    abstract::The European Commission and the European Parliament have acknowledged the specific need for a proper evaluation of new drugs in children. The evaluation of the antiepileptic drugs (AEDs) available on the market illustrates the deficit in therapeutic trials for childhood epilepsy syndromes. Currently, the development o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868010-00002

    authors: Chiron C,Dulac O,Pons G

    更新日期:2008-01-01 00:00:00

  • Clostridium difficile-associated disease: changing epidemiology and implications for management.

    abstract::Clostridium difficile-associated disease (CDAD) is increasingly being reported in many regions throughout the world. The reasons for this are unknown, are likely to be multifactorial, and are the subject of several current investigations. In addition to the upsurge in frequency of CDAD, an increased rate of relapse/re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767040-00001

    authors: Owens RC

    更新日期:2007-01-01 00:00:00

  • Pharmacotherapy for oesophagogastric cancer.

    abstract::Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767170-00006

    authors: Jackson C,Starling N,Chua YJ,Cunningham D

    更新日期:2007-01-01 00:00:00

  • Pharmacotherapy for hepatic encephalopathy.

    abstract::Hepatic encephalopathy (HE) is a challenging clinical complication of liver dysfunction with a wide spectrum of neuropsychiatric abnormalities that range from mild disturbances in cognitive function and consciousness to coma and death. The pathogenesis of HE in cirrhosis is complex and multifactorial, but a key role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10898630-000000000-00000

    authors: Phongsamran PV,Kim JW,Cupo Abbott J,Rosenblatt A

    更新日期:2010-06-18 00:00:00

  • Clascoterone: First Approval.

    abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01417-6

    authors: Dhillon S

    更新日期:2020-11-01 00:00:00

  • Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

    abstract::When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have demonstrated that entacapone ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059060-00004

    authors: Kaakkola S

    更新日期:2000-06-01 00:00:00

  • Lixisenatide: first global approval.

    abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0033-3

    authors: Elkinson S,Keating GM

    更新日期:2013-03-01 00:00:00

  • Somatropin (Zorbtive): in short bowel syndrome.

    abstract::A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464120-00008

    authors: Keating GM,Wellington K

    更新日期:2004-01-01 00:00:00

  • Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.

    abstract::The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy. For the subgroup of patients with inoperable gastrointestinal stromal tumour (GIST), progress has been made...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565020-00002

    authors: Hartmann JT,Patel S

    更新日期:2005-01-01 00:00:00

  • Parenteral aminoglycoside therapy. Selection, administration and monitoring.

    abstract::Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447060-00004

    authors: Kumana CR,Yuen KY

    更新日期:1994-06-01 00:00:00

  • Methotrexate in rheumatoid arthritis. An update.

    abstract::Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by several regulatory agencies, including the Food and Drug Administration. The tendency is now to prescribe it at earlier stages of the disease. Methotrexate is a well known antifolate. Its exact mechanism of action in rheumatoid arth...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447010-00003

    authors: Bannwarth B,Labat L,Moride Y,Schaeverbeke T

    更新日期:1994-01-01 00:00:00

  • Steroid-refractory severe ulcerative colitis: what are the available treatment options?

    abstract::Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868090-00001

    authors: Moss AC,Peppercorn MA

    更新日期:2008-01-01 00:00:00

  • Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines.

    abstract::During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958003-00016

    authors: Diasio RB

    更新日期:1999-01-01 00:00:00

  • Fetal pharmacotherapy.

    abstract::Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262050-00004

    authors: Koren G,Klinger G,Ohlsson A

    更新日期:2002-01-01 00:00:00

  • Current use and future potential role of retinoids in dermatology.

    abstract::Since their introduction 15 years ago, retinoids have been increasingly used for topical and systemic treatment of psoriasis and other hyperkeratotic and parakeratotic skin disorders, keratotic genodermatoses, severe acne and acne-related dermatoses, and also for therapy and/or chemoprevention of skin cancer and other...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753030-00003

    authors: Orfanos CE,Zouboulis CC,Almond-Roesler B,Geilen CC

    更新日期:1997-03-01 00:00:00

  • Simple analgesics.

    abstract::A number of drugs are available that act fairly specifically as "mild" analgesics, although this description by no means implies that their clinical effectiveness is limited to the relief of slight pain and trivial disability. They are effective by mouth and their action is mediated peripherally. Among the possible me...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197510050-00007

    authors: Parkhouse J

    更新日期:1975-01-01 00:00:00

  • The role of anaerobic bacteria in mediastinitis.

    abstract::The management of mediastinitis involves directing appropriate antibacterial therapy against the potential bacterial pathogens. The increased recovery of anaerobic bacteria from mediastinal infections has led to a greater appreciation of their role in this condition and to re-evaluation of the proper treatment of this...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666030-00004

    authors: Brook I

    更新日期:2006-01-01 00:00:00

  • Pharmacotherapy of ectoparasitic infections.

    abstract::Epizoonoses such as scabies, lice and cimicosis are common, vexing disorders that occur worldwide. Historically, many treatment modalities have been employed in the management of these disorders, and most of the drugs described in this review are of historical interest and no longer recommended or in widespread use be...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161080-00004

    authors: Roos TC,Alam M,Roos S,Merk HF,Bickers DR

    更新日期:2001-01-01 00:00:00

  • Prevention of perinatal HIV transmission: current status and future developments in anti-retroviral therapy.

    abstract::Significant progress has been made in the battle against transmission of HIV-1 from mother to infant. Antiretroviral regimens covering the later part of gestation, labour and the first few weeks of neonatal life have shown great efficacy in reducing such transmission. With the advent of combination antiretroviral ther...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262150-00004

    authors: Kourtis AP

    更新日期:2002-01-01 00:00:00

  • Prospects for the development of new treatments with a rapid onset of action in affective disorders.

    abstract::Several compounds have been claimed to have a faster onset of antidepressant action. However, these trials suffered from lack of appropriate definitions and of standardised and comparable methodology, as far as measurement instruments, dosage strategies and statistical analyses were concerned. This article was underta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00001

    authors: Soares JC,Gershon S

    更新日期:1996-10-01 00:00:00

  • Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs.

    abstract::Evidence suggests that arterial hypertension, in addition to being a cardiovascular and renal risk factor, may also be associated with an impairment of male sexual function. Since other cardiovascular risk factors, especially diabetes mellitus, have also been shown to correlate with impaired sexual function it has bee...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565060-00005

    authors: Düsing R

    更新日期:2005-01-01 00:00:00

  • Antibacterials as adjuncts to incision and drainage for adults with purulent methicillin-resistant Staphylococcus aureus (MRSA) skin infections.

    abstract::The annual incidence of skin and soft tissue infections (SSTIs) has nearly tripled in the US since the early 1990s. Many purulent SSTIs in the community setting are caused by methicillin-resistant Staphylococcus aureus (MRSA). Incision and drainage (I&D) are indicated for most purulent MRSA infections; however, the us...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11599510-000000000-00000

    authors: Forcade NA,Wiederhold NP,Ryan L,Talbert RL,Frei CR

    更新日期:2012-02-12 00:00:00